Patient reported outcomes in the assessment of premature ejaculation

被引:14
作者
Althof, Stanley E. [1 ,2 ]
机构
[1] Ctr Marital & Sexual Hlth South Florida, 1515 N Flagler Dr,Suite 540, W Palm Beach, FL 33401 USA
[2] Case Western Reserve Univ, Sch Med, Cleveland, OH 44106 USA
关键词
Patient reported outcomes (PRO); questionnaire; outcome measures; diagnosis; SEXUAL SATISFACTION; INTEGRATED ANALYSIS; DOUBLE-BLIND; VALIDATION; DAPOXETINE; EFFICACY; INDEX; MEN;
D O I
10.21037/tau.2016.05.04
中图分类号
R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
摘要
The term 'Patient Reported Outcome', abbreviated as PRO, was introduced by the US Food and Drug Administration (FDA) which proposed guidance on the development and validation of PROs. Previously PROs were known as self-report diaries, event-logs, self-administered questionnaires, and clinician administered rating scales. PROs seek to capture the subjective perceptions of patients and/or partner's related to their specific symptoms, degree of bother, efficacy of a medication or psychotherapy intervention, and quality of life issues related to a specific condition. This article reviews the essential psychometric and regulatory agency requirements in the development of PROs. The constructs of reliability, various forms of validity, sensitivity, and specificity as well as concerns with translating a PRO into a different language are reviewed. Three PROs, the Premature Ejaculation Profile (PEP), the Index of Premature Ejaculation (IPE) and the Premature Ejaculation Diagnostic Tool (PEDT) all used in the assessment of premature ejaculation (PE) are discussed. These questionnaires meet or exceed all the psychometric requirements and have been employed in clinical trials and observational studies of men with PE. The article concludes on discussing some of the limitations of PRO use and recommendations for the future.
引用
收藏
页码:470 / 474
页数:5
相关论文
共 50 条
  • [31] Selective serotonin reuptake inhibitors in the treatment of premature ejaculation
    Wang Wei-fu
    Chang Le
    Minhas, Suks
    Ralph, David J.
    CHINESE MEDICAL JOURNAL, 2007, 120 (11) : 1000 - 1006
  • [32] Baseline Characteristics and Treatment Outcomes for Men with Acquired or Lifelong Premature Ejaculation with Mild or No Erectile Dysfunction: Integrated Analyses of Two Phase 3 Dapoxetine Trials
    Porst, Hartmut
    McMahon, Chris G.
    Althof, Stanley E.
    Sharlip, Ira
    Bull, Scott
    Aquilina, Joseph W.
    Tesfaye, Fisseha
    Rivas, David A.
    JOURNAL OF SEXUAL MEDICINE, 2010, 7 (06) : 2231 - 2242
  • [33] Topical Agents for Premature Ejaculation: A Review
    Butcher, Michael J.
    Zubert, Tricia
    Christiansen, Kristin
    Carranza, Alejandro
    Pawlicki, Paul
    Seibel, Stacey
    SEXUAL MEDICINE REVIEWS, 2020, 8 (01) : 92 - 99
  • [34] DAPOXETINE: A NOVEL TREATMENT FOR PREMATURE EJACULATION
    Owen, Richard T.
    DRUGS OF TODAY, 2009, 45 (09) : 669 - 678
  • [35] Surgery is not indicated for the treatment of premature ejaculation
    Anaissie, James
    Yafi, Faysal A.
    Hellstrom, Wayne J. G.
    TRANSLATIONAL ANDROLOGY AND UROLOGY, 2016, 5 (04) : 607 - 612
  • [36] AVAILABLE AND FUTURE THERAPIES FOR PREMATURE EJACULATION
    Hellstrom, W. J. G.
    DRUGS OF TODAY, 2010, 46 (07) : 507 - 521
  • [37] New Therapeutic Perspectives in Premature Ejaculation
    Paco, Joana Simoes
    Pereira, Bruno Jorge
    UROLOGY, 2016, 88 : 87 - 92
  • [38] Patient-Reported Outcomes and Fibromyalgia
    Williams, David A.
    Kratz, Anna L.
    RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 2016, 42 (02) : 317 - +
  • [39] Central regulation of ejaculation and the therapeutic role of serotonergic agents in premature ejaculation
    Patel, Kush
    Hellstrom, Wayne J. G.
    CURRENT OPINION IN INVESTIGATIONAL DRUGS, 2009, 10 (07) : 681 - 690
  • [40] An up-to-date overview of the pharmacotherapeutic options for premature ejaculation
    Mitsogiannis, Iraklis
    Dellis, Athanasios
    Papatsoris, Athanasios
    Moussa, Mohamd
    EXPERT OPINION ON PHARMACOTHERAPY, 2022, 23 (09) : 1043 - 1050